Orchard Therapeutics plc
ORTX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $176,544 | $98,618 | $76,151 | $47,438 |
| - Cash | $23,469 | $38,273 | $61,487 | $68,424 |
| + Debt | $47,820 | $50,513 | $53,270 | $58,090 |
| Enterprise Value | $200,895 | $110,858 | $67,934 | $37,104 |
| Revenue | $6,302 | $7,314 | $1,237 | $6,986 |
| % Growth | -13.8% | 491.3% | -82.3% | – |
| Gross Profit | $4,557 | $5,125 | $870 | $8,891 |
| % Margin | 72.3% | 70.1% | 70.3% | 127.3% |
| EBITDA | -$34,623 | -$19,513 | -$19,676 | $133,797 |
| % Margin | -549.4% | -266.8% | -1,590.6% | 1,915.2% |
| Net Income | -$35,319 | -$12,307 | -$17,412 | $134,894 |
| % Margin | -560.4% | -168.3% | -1,407.6% | 1,930.9% |
| EPS Diluted | -1.55 | -0.65 | -1.23 | 10.52 |
| % Growth | -138.5% | 47.2% | -111.7% | – |
| Operating Cash Flow | -$23,892 | -$27,833 | -$29,508 | -$12,084 |
| Capital Expenditures | -$126 | $31 | -$514 | -$484 |
| Free Cash Flow | -$24,018 | -$27,802 | -$30,022 | -$12,568 |